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Abstract
Background: There is an increasing recognition of epidemics of primarily tubular-interstitial chronic kidney disease
(CKD) clustering in agricultural communities in low- and middle-income countries (LMICs). Although it is currently
unclear whether there is a unified underlying aetiology, these conditions have been collectively termed CKD of
undetermined cause (CKDu). CKDu is estimated to have led to the premature deaths of tens to hundreds of
thousands of young men and women over the last 2 decades. Thus, there is an urgent need to understand the
aetiology and pathophysiology of these condition (s). International comparisons have provided the first steps in
understanding many chronic diseases, but such comparisons rely on the availability of standardised tools to
estimate disease prevalence. This is a particular problem with CKD, since the disease is asymptomatic until the late
stages, and the biases inherent in the methods used to estimate the glomerular filtration rate (GFR) in population
studies are highly variable across populations.
Method: We therefore propose a simple standardised protocol to estimate the distribution of GFR in LMIC
populations – The Disadvantaged Populations eGFR Epidemiology (DEGREE) Study. This involves the quantification
of renal function in a representative adult population-based sample and a requirement for standardisation of serum
creatinine measurements, along with storage of samples for future measurements of cystatin C and ascertainment
of estimates of body composition, in order to obtain valid comparisons of estimated GFR (eGFR) within and
between populations.
Discussion: The methodology we present is potentially applicable anywhere, but our particular focus is on
disadvantaged populations in LMICs, since these appear to be most susceptible to CKDu. Although the protocol
could also be used in specific groups (e.g. occupational groups, thought to be at excess risk of CKDu) the primary aim
of the DEGREE project is characterise the population distribution of eGFR in multiple regions so that international
comparisons can be performed. It is only with a standardised approach that it will be possible to estimate the scale of,
and variation in, impaired kidney function between affected areas. These data should then provide insights into
important social, demographic and environmental risk factors for this increasingly recognised disease.
Keywords: Chronic kidney disease of undetermined cause, Low- and middle-income countries, Mesoamerican
nephropathy, Estimated glomerular filtration rate, Chronic kidney disease prevalence
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Background
Chronic impairment of kidney function is most com-
monly associated with diabetic nephropathy, vascular
disease, glomerulonephritis, congenital abnormalities or
obstruction of the urinary tract. Although such impair-
ment is usually asymptomatic in the early stages, the
prevalence of end-stage renal disease requiring renal re-
placement therapy is increasing worldwide [1]. Much of
this increase can be attributed to an increasing preva-
lence of known risk factors. However, there is now also
increasing recognition of forms of progressive kidney
injury which are not associated with diabetes, vascular
disease, or glomerulonephritis, and which are affecting
the working-age populations of low- and middle- income
countries (LMICs).
This chronic impairment of kidney function not asso-
ciated with known risk factors or a specific histological
diagnosis has been termed CKD of undetermined cause
(CKDu). Other terms used include CKD of non-traditional
cause (CKDnt) and Mesoamerican nephropathy (MeN)
when describing the condition in parts of Latin America.
For the purposes of this paper we will use the term CKDu.
Clusters of CKDu occur in primarily (but perhaps not ex-
clusively) in communities characterised by a hot climate
and reliance on heavy agricultural work. Although various
causal and contributing factors have been proposed there is
currently no definitive evidence for the role of a specific
aetiological pathway. CKDu carries a poor prognosis, as
renal replacement therapy is often inaccessible to the ma-
jority of the population in many of the affected areas. Over
the last two decades, clusters of CKDu have been reported
in Central America [2] and Sri Lanka [3]. Other reports
have suggested that similar patterns may be occurring in re-
gions of India [4], Saudi Arabia [5], Egypt [6], and Senegal
[7]. However, significant difficulties arise in comparing
studies conducted in different regions due to differing study
designs, sampling approaches and case-definitions. Further-
more, the impact of CKDu on those affected, and the
resulting strain on health systems, makes the estimation of
CKDu prevalence a global health priority.
In the past, international comparisons have played a
key role in identifying possible causes of chronic disease
[8]. For example, many of the discoveries on the causes
of cancer (including dietary factors and colon cancer,
hepatitis B and liver cancer, aflatoxins and liver cancer,
human papilloma virus and cervical cancer) have their
origins, directly or indirectly, in the systematic inter-
national comparisons of cancer incidence conducted in
the 1950’s and 1960’s. These suggested hypotheses con-
cerning the possible causes of the international patterns,
which were investigated in more depth in further stud-
ies. In some instances these hypotheses were consistent
with biological knowledge at the time, but in other in-
stances they were new and striking, and might not have
been proposed, or investigated further, if the population
level analyses had not been done.
A more recent example of the value of international
comparisons and collaborations is the International
Study of Asthma and Allergies in Childhood (ISAAC) a
standardised protocol to estimate the prevalence of
asthma internationally [9, 10]. The most recent phase
(Phase Three) has involved 1,187,496 children in 237
centres in 98 countries [11–13]. This has led to greater
understanding of the possible causes of asthma globally,
as well as the creation of a large international network
of researchers. We propose a similar model involving
a simple and practical protocol to estimate distribu-
tions of renal function in disadvantaged communities
globally: the Disadvantaged Populations estimated
Glomerular Filtration Rate (eGFR) Epidemiology Study
(DEGREE). This will provide key information to in-
form hypotheses and to guide further research into
the causes of CKDu.
Challenges
A number of challenges arise when attempting to obtain
standardized estimates of CKDu prevalence globally:
1. CKDu is usually clinically silent until it has
progressed to advanced stages, so the diagnosis of
mild renal impairment must be made by testing
asymptomatic individuals.
2. Awareness of CKDu is highly variable so attempts to
determine disease burden using routine healthcare
data or mortality records may be misleading.
3. Variation in access to renal replacement therapy
both within and between regions means that dialysis
or transplant registry data are also unlikely to reflect
disease prevalence.
4. Unlike CKD due to causes such as diabetes or
glomerulonephritis, CKDu is associated with a low
prevalence of hypertension and significant
proteinuria, at least in the early stages. Therefore
commonly instituted mass non-communicable
disease screening tools such as blood pressure
measurement or dipstick urinalysis have poor
sensitivity for detecting cases of CKDu in a population.
5. Renal biopsies are unlikely to be performed
systematically in affected populations; where these
have been undertaken they have generally not
demonstrated specific findings, making tissue
diagnosis of CKDu difficult. Similarly, ultrasound
and other types of renal imaging are usually non-
informative.
6. The distribution of the GFR and the extent to which
this measure predicts end-stage renal disease is not
well characterised in the affected populations and
may vary between regions.
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7. Estimates of GFR from serum markers such as
creatinine, e.g. using the eGFR calculated by
either the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) or Modified Diet in Renal
Disease (MDRD) equations, become more imprecise
as the level of GFR approaches normal [14].
8. The degree of bias in these estimates of GFR is also
a function of ethnicity, and body weight/muscle
mass [14], and, the precision of ethnicity-adjusted
equations is still highly variable across geographic
regions [15] rendering international comparisons
particularly problematic.
9. GFR estimation based on serum markers is
critically dependent on adequate standardization
of assays [16].
10. Finally, the definition of CKDu is currently one of
exclusion. The causes to be excluded may change
over time as our knowledge increases. Thus, the
various phenotypes, and their definitions, may
change over time.
Rationale
For the above reasons, the protocols presented here are
not intended to yield definitive information on CKDu
prevalence. Rather, they are intended to yield standard-
ized estimates of the distribution of eGFR, and hence
the prevalence of reduced renal function, a precursor of
CKD in general, and CKDu in particular. Since defini-
tions of CKDu are currently controversial and changing
(in particular, this is a definition by exclusion, and may
be refined in future), the aim is not to definitely estimate
the prevalence of CKDu itself, but rather to obtain the
key information that can be used in a variety of defini-
tions of CKDu in future. Nevertheless, we of course also
propose collecting information on other causes of CKD
(e.g. diabetes), and use these (by exclusion) to identify
possible cases of CKDu, and more generally of impaired
renal function which is not due to known causes.
It is clear that differences in creatinine assay calibra-
tion have contributed to a large proportion of the total
variability in reported eGFR values in epidemiological
studies to date [17]. Failure to use standardised serum
creatinine values for international comparisons would
therefore lead to quantification of variability in laboratory
practice rather than comparisons of eGFR distributions.
Therefore any eGFR data submitted to the DEGREE pro-
ject must use serum creatinine values that are measured
by assays calibrated using quality controls traceable to an
isotope dilution mass spectrometry (IDMS) standard.
Calibration results and quality control information will
also need to be submitted with study data.
It should be recognised that there is no single validated
easily deliverable solution to the issue of differential bias
in GFR estimating equations between populations/ethnic
groups. In the DEGREE protocol this problem will be ad-
dressed by two main approaches to allow us to perform
meaningful international comparisons, these are: (i) stor-
age of samples for centralised cystatin C measurement
and (ii) collection of estimates body composition. In
addition we hope to support the performance of measured
GFRs in subpopulations in selected centres. Although
both sample storage for central cystatin C assays and
bioimpedence measurements are currently included in the
core protocol it may be that as the DEGREE project
grows, alongside the validation of eGFR equations in dif-
ferent populations, these aspects of the protocol can be
further simplified.
Cystatin C is an endogenous marker of kidney func-
tion less dependent on muscle mass. Both costs and lack
of standardisation across different laboratories [18] mean
that locally performed cystatin C measurements are not
currently suited to international comparisons. Further-
more although methods based on this test have gener-
ally been shown to improve the precision of eGFR
measurements [19], there are other non-renal sources
of variation in cystatin C [20], and this approach has
not yet been validated in many of the populations of
interest. However with collaborative efforts aimed at
both assay standardisation and validation, cystatin C
based eGFR estimation is likely to go on to become the
marker on which eGFR is calculated locally in the fu-
ture. Meanwhile the DEGREE committee plans to pro-
vide the opportunity to measure cystatin C centrally
for a number of centres and therefore storage of sam-
ples for this purpose is included in part of the core
protocol.
The second approach uses diet and body composition
data, which will be collected in parallel as part of the
protocol using single frequency 50Hz bioimpedence de-
vices along with self-reported meat consumption. Ad-
justment of measures of creatinine based renal clearance
for estimates of creatinine production have been shown
to provide a more precise estimate of excretory function
across a range of physical builds and renal function
[21, 22]. Simple bioimpedence devices produce highly
reproducible measurements, are now routinely in use
by nutritional researchers globally and are available
cheaply. Although body composition estimates from
bioimpedence data may also be subject to ethnicity-
dependent bias, the magnitude of this measurement error
can be minimised using a simplified approach and is sub-
stantially smaller than that observed with GFR estimating
equations [23, 24].
The DEGREE committee are keen that investigators
are not dissuaded from performing studies by the inclu-
sion of the above aspects in the protocol. Therefore any
research group keen to undertake a DEGREE study, but
feel they are unable to store samples for later cystatin C
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estimation and/or collect body composition data are ad-
vised to contact the DEGREE executive.
Finally, although it is recognised that these procedures
will be beyond the resources of many centres, we also
hope some research teams will be interested in perform-
ing measured GFRs using simplified iohexol clearance
techniques in a subsample of the population in some
centres [25]. These procedures will provide insight into
the validity of GFR estimates across the range of kidney
function using endogenous markers in the relevant pop-
ulations. A number of research teams are pursuing this
type of study independently however the executive
would be keen to support investigators to perform these
protocols in the populations that are the focus of the
DEGREE project. Interested centres can contact the DE-
GREE executive.
Aims
Taking the above challenges and rationale into account
the aims of the DEGREE collaboration are to:
1. Conduct representative surveys of the distribution of
eGFR in populations in different regions and to
make regional and international comparisons.
2. Estimate the proportion of those with reduced eGFR
but without diabetes, hypertension or proteinuria in
each population and compare this between regions
and internationally.
3. Generate baseline data so that future shifts in the
eGFR distribution in affected areas can be
determined.
4. Provide the basis for future standardised studies,
including but not limited to: detailed phenotypic
examinations, environmental investigations,
quantification of occupational exposures, cohort
studies and interventional trials
5. Establish a framework for international collaboration
and foster an environment for further work into the
prevalence and causes of CKDu.
Design
Organisation of the DEGREE project
The DEGREE project is an international collaboration
involving standardized protocols for estimating popula-
tion patterns of eGFR. Individual centres can register
with the DEGREE study by submitting a registration
document (Additional file 1). A number of study sites
have either commenced, or are in the planning stages of,
i.e. awaiting the outcome of funding decisions, studies
with protocols using the DEGREE methodology (with
minor modifications in some cases). Centres will be re-
quired to follow the standardised core protocol in order
to be part of the DEGREE collaboration, and to be in-
cluded in international comparisons. However, investigators
will be encouraged to enhance this minimum protocol with
additional investigations as appropriate to the local situ-
ation. Possible examples include: additional questions fo-
cused on work exposures, renal ultrasound imaging, formal
albumin:creatinine ratio measurements. Example profor-
mas for some of these additional modules are available in
the Additional file 2 or from the authors.
Core protocol - ethical and regulatory issues
Participants will need to provide informed consent be-
fore taking part in the study, and Investigators will be re-
sponsible for producing participant information sheets
and gaining approval from the local institutional review
board. It is envisaged that eGFR results will be commu-
nicated back to participants once available. The need for
repeat testing in those subjects with raised serum cre-
atinine levels, the impact of abnormal findings on those
taking part (including newly diagnosed low eGFR, glyco-
suria or hypertension), as well as mechanisms for on-
ward referral to local healthcare systems will constitute
an important aspect of the ethical framework in which
this protocol is undertaken. These issues should be for-
malised into the local version of the protocol before
commencing a DEGREE study. Furthermore, the need
for close collaboration with the local and national health
system during the planning phase of a DEGREE study
includes not only the system for individuals in need
of follow up, but also agreements on how results
from the DEGREE study at the population level
should be communicated to different stakeholders for
public health purposes.
Core protocol - questionnaires and study instruments
The aims of the core questionnaire and clinical measure-
ments are to obtain a minimum core dataset to allow
the estimation of the distribution of eGFR within and
between populations, and to estimate the prevalence of
reduced GFR that is not due to diabetes, glomerulo-
nephritis or associated with hypertension. Investigators
should add additional questions on exposures that are
relevant to the local context or concerns of the popula-
tion. The questionnaires and protocols (see Additional
file 3) have been developed by modification of the
STEPS instruments [26]. Translation and validation of
questionnaires into other languages so that all groups
within a region can participate will be the responsibility
of local coordinators. Questionnaires should be con-
ducted in a language spoken by all participants or trans-
lators recruited where participants may not all speak the
same language.
Core protocol - population and sampling strategy
For robust international comparisons a representative
population is critical. The protocol should be undertaken
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in randomly–selected sample (or alternatively the entire
population) of adults aged over 18 years in a specified
geographical area (i.e. study participants must not be se-
lected based on them presenting to healthcare facilities
or advertised screening sessions). A region or district
should be selected and clearly defined using GIS coordi-
nates or map. Sampling units can be individuals or
households; in the former case, a new census should be
conducted unless an up-to-date and complete census is
already available for the entire defined area. This
protocol may of course also be applied in specific
populations, for example occupational groups, but
studies based on non-representative samples will not
be used for international comparisons in the first
phase of the DEGREE project.
The ideal sample size for a population-based study
(see below) is 1000 participants per study centre, and
this is required for inclusion in international compari-
sons, but it is recognised that studies smaller than this
and in specific populations, particularly in occupational
groups, may generate valuable information.
Core protocol - study visits
The study visit will involve the administration of the
core questionnaire, basic clinical measurements, dipstick
urinalysis and a blood draw for serum creatinine
measurement (proformas for these are included as
Additional file 3). Where possible participants should
be asked to attend first thing in the morning and
fasted overnight, i.e. before the first meal of the day
and before starting work.
Core protocol - testing
Dipstick urinalysis should be performed using commer-
cial testing sticks according to manufacturers instruc-
tions. Sticks should report urine blood, protein (at
macroalbminuric level), leucocytes, glucose, pH and spe-
cific gravity as a minimum and ideally read using an
optical reader. Serum creatinine should be measured lo-
cally using a method calibrated to an isotope dilution
mass spectrometry standard with assay and calibration
details reported to the DEGREE data centre. Height
should be measured using a stadiometer and weight
using digital scales. Body composition should be quanti-
fied using calibrated single frequency (50 kHz) bioimpe-
dence analysis instrument (supine instrument where
possible) as a direct impedance output, with machine-
calculated values also reported (examples and suppliers
of suitable instruments can be obtained from the DE-
GREE executive). Additional bio-samples (e.g. whole
blood, serum and urine) should be collected and stored
at -20C (or lower where possible) to allow for cross-
centre validation of serum creatinine values and the test-
ing of additional markers of renal function such as
cystatin C as discussed above. The number and type of
these samples will depend on local circumstances but we
suggest a minimum of one additional serum sample
(total 5 mL stored as three 1.5 mL aliquots) for each
participant. These samples should be handled in accord-
ance with local standard operating procedures with ap-
propriate attention to labelling, storage, equipment
maintenance and documentation [27].
Core protocol - data management and reporting
All DEGREE protocols are freely available to inter-
ested investigators. Each individual Centre will ‘own’
their own data, but will be asked to submit an anon-
ymised copy of individual level data, together with
contextual information on the investigated population
to the DEGREE Data Centre for inclusion in inter-
national comparisons.
Paper based studies should use double data-entry to
minimise human manual transcription error. Samples
and questionnaires will ideally be identified using a bar-
code system. Centres can submit their cleaned data
using sample database available from the DEGREE team
based in London.
A number of ongoing projects are currently attempt-
ing to assess the performance of eGFR estimating equa-
tions in different regions and developing ethnicity
specific modifications. Until these are available, data
should be provided as serum creatinine estimates to en-
able standardised calculation at the analysis centre with
a variety of formulae.
International comparisons
International comparisons will be conducted and coordi-
nated by the DEGREE Steering Committee. Descriptive
statistics of eGFR using both CKD-EPI and MDRD for-
mulae (with and without adjustment for body compos-
ition and self-reported meat consumption) will be
presented by country, region, age and sex. The distribu-
tions of eGFR will be estimated in the full sample, and
then restricted to those without evidence of hyperten-
sion, diabetes, or urinary evidence of glomerulopathy.
As secondary analyses we will investigate the preva-
lence of people with eGFR < 90 ml/min restricted to
those without hypertension, diabetes, or urinary evi-
dence of glomerulopathy, adjusted for age, sex and
body composition.
Reporting to the DEGREE data centre should be in ac-
cordance with previous guidelines [28]. This includes de-
scription of the sampling frame, the characteristics of
the population, the sampling method, response rates and
the methodology used for laboratory and clinical mea-
surements. Example reporting forms are presented in
the Additional file 3.
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Study size and power
The required study size has been estimated based on two
considerations: (i) obtaining reasonably accurate estimates
of eGFR in each centre; (ii) having sufficient statistical
power for comparisons between centres or between popu-
lation subgroups. For both these considerations, the
power calculations have been done two ways: (i) using
eGFR as a continuous variable (mean, sd) in order to esti-
mate the population prevalences of impaired kidney func-
tion and (ii) ‘cutoffs’ for eGFR. The overall aim is to have
sufficient statistical power to estimate prevalence, and de-
tect population differences of epidemiological and health
service significance.
Overall, a recommended sample size of 1,000 partici-
pants has been chosen.
Estimates within a single population: Using a con-
tinuous measure if the ‘true’ mean eGFR is 110 mL/
min (although it is recognised this value is likely to
vary substantially between different regions), with a
standard deviation (SD) of 30 mL/min it is more than
95% likely that the estimated mean will be between
108 mL/min and 112 mL/min. Assuming a ‘true’
prevalence of eGFR <90 mL/min of 5%, then with a
sample size of 1,000, it is 95% likely that the esti-
mated prevalence will be between 3.6% and 6.4%.
Comparisons between populations: Using a continuous
measure if one population has a mean eGFR 5 mL/min
lower than that in another population, the study will
have more than 95% power to detect this difference; for
comparisons between population subgroups (e.g. three
subgroups of equal size), the study will have more than
80% power to detect a difference of 7 mL/min in mean
eGFR. If one centre has a prevalence of impaired kidney
function (eGFR <90 mL/min) of 5% and another centre
has double the risk (i.e. prevalence of 10%), then a sam-
ple size of 1,000 will provide 99% power to detect this
difference; for comparisons within centres, if the centre
participants are divided into three equal groups, the
study will have approximately 80% power to detect a
doubling of risk when comparing any two of the three
subgroups.
Future plans
Prevalence studies are the basis on which the popula-
tions and study design for further investigations can
be determined. Once variation in eGFR distribution
and estimates of CKD and CKDu prevalence have
been established, appropriately designed aetiological
studies can be pursued. In collaboration with other
investigators we will continue to develop protocols
for follow-up studies (examining the roles of occupa-
tional and environmental factors) and intervention
studies in affected populations.
Discussion
Weaknesses
This study involves cross-sectional surveys rather than
repeated measures. Thus, it can identify population pat-
terns, but cannot be used to diagnose CKDu in individ-
uals, since the clinical diagnosis of CKD by impaired
kidney function requires estimation of eGFR and pro-
teinuria on two occasions at least 3 months apart (as a
single measurement does not exclude an acute kidney
injury; AKI). However, most participants are unlikely to
be acutely unwell in a population sample, and therefore
there is little evidence that AKI cases would affect the
eGFR distribution as a whole in the study sample.
As mentioned above, the major challenges of perform-
ing international CKD comparisons are those of stand-
ardisation of serum creatinine measurements and those
surrounding the differential bias using GFR estimating
equations when comparing study participants of differ-
ent ethnicities. With regard to GFR estimation this is
likely to be a particular problem when characterising the
upper end of the GFR distribution of the population ra-
ther than estimating the prevalence of advanced CKD.
However, as international comparisons of advanced
CKD alone would require prohibitively large sample
sizes we have elected to compare the entire eGFR distri-
bution between populations.
With recent international efforts the obstacle of lack
of serum creatinine assay standardisation between la-
boratories has been largely overcome, however there
are no validated methods to address the problem of
differential bias in eGFR equations suitable for epi-
demiological studies. In an attempt to address what
are likely to be the largest contributor to differential
bias inherent in GFR estimating equations the DEGREE
protocol includes both sample collection for future
cystatin C measurements and data collection on body
composition and self-reported meat consumption.
Whole body bioimpedance is a simple but reasonable
indicator of lean mass index and should allow a more
robust comparison of eGFR between populations.
Once improved estimating equations validated in the
relevant populations and/or standardised cystatin C
measurements become available, re-analysis of data-
sets will be performed.
Given the resource implications of undertaking for-
mal albumin:creatinine ratios, we have opted for the
simplest option, dipstick urinalysis, in the core proto-
col. Previous large-scale epidemiologic studies have
demonstrated the predictive value of urine dipstick
measurements using electronic readers (and where
possible we advise these to be used) [29]. However if
resources are available to store urine samples the pos-
sibility of measuring albumin:creatinine ratios could
be explored.
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Governance
The DEGREE organisational structure comprises a
Steering Committee (including the authors of this proto-
col) coordinated by an Executive (chaired by the first
and last authors of this paper, and also including co-
authors KJ, JG, AS and RC-R). A Reference Group will
provide advice to the Steering Committee. Regional
coordinators will be responsible for identifying lead in-
vestigators and facilitating local investigators. These co-
ordinators will be encouraged to visit study sites.
Expressions of interest for the reference group, and re-
gional coordinators should be directed to the DEGREE
Study Executive. In general, publications on inter-
national comparisons will be authored by the DEGREE
Study Group, comprising members of the Steering Com-
mittee, coordinators, and a co-investigator from each
participating centre.
The DEGREE executive is committed to maximizing
the use of a common protocol to allow robust inter-
national comparisons. To this end, the project has been/
will be promoted, and the rationale underlying the
protocol presented, at a number of international meet-
ings including the 2015 Mesoamerican Nephropathy
Workshop, 2016 Institute for Global Development India
meeting on CKDnt, the 2016 World Health Organisation
Workshop on CKDu in Sri Lanka and the 2016 Epidemi-
ology in Occupational Health Conference (EPICOH). In
addition the DEGREE collaboration will continue to
work with key stakeholders, including but not limited to:
the Consortium on the Epidemic of Nephropathy in
Central America and Mexico, the International Society
of Nephrology and the Inter-American Development
Bank. Funding has been identified for engagement and
communications and a DEGREE website, hosting proto-
cols and other resources, will soon be available via the
London School of Hygiene and Tropical Medicine
Centre for Non-Communicable diseases (http://globalncds.
lshtm.ac.uk). Most importantly however, the DEGREE col-
laboration will support local investigators with training and
networking as well as assisting them in obtaining the neces-
sary resources to conduct these studies.
Additional modules
A number of further optional additional modules will be
made available through the DEGREE Steering Commit-
tee. Specifically we plan to develop tools that allow occu-
pational and environmental exposures to be captured
using standardised tools.
Conclusions
We have here presented the core DEGREE Study proto-
col for measuring population patterns of eGFR. We will
develop additional modules for follow-up studies (e.g.
examining the roles of occupational and environmental
factors) and intervention studies in affected populations.
Even in the first stage of DEGREE, the use of a common
prevalence protocol will yield important information on
population patterns and time trends, thus enabling us to
gain a better understanding of the scope and scale of
CKD, and the possible causes. This will provide a basis
for further efforts to address the epidemic of kidney fail-
ure that is affecting disadvantaged populations around
the world.
Additional files
Additional file 1: DEGREE Centre Data. (DOC 154 kb)
Additional file 2: DEGREE Additional Optional Renal Protocol. (DOC 94 kb)
Additional file 3: DEGREE Core Protocol Proforma. (DOC 203 kb)
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